AOA Versus Non-AOA in Low Prognosis Patients by the POSEIDON Criteria (NCT05402605) | Clinical Trial Compass
UnknownNot Applicable
AOA Versus Non-AOA in Low Prognosis Patients by the POSEIDON Criteria
Vietnam528 participantsStarted 2022-08-29
Plain-language summary
Poor ovarian response (POR) remains one of the significant challenges of Assisted Reproductive Technology (ART). Facing difficulties related to clinical practice, optimizing the embryo culture process is necessary to improve the embryo number and quality in this group of patients. Potential techniques mentioned in the current literature include follicular size at trigger, dual trigger, artificial oocyte activation (AOA), blastocyst transfer, and the role of preimplantation genetic testing for aneuploidy (PGT-A). AOA is currently expected to improve treatment outcomes in poor ovarian responders with the potential for clinical efficacy. However, this issue has not been evaluated before.
Who can participate
Age range
35 Years – 45 Years
Sex
FEMALE
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Was diagnosed as low prognosis patients by the POSEIDON criteria in group 4: maternal age ≥ 35 years old, AMH \< 1,2 ng/ml and AFC \< 5
* Cycles ≤ 3
* Oocytes could be collected with OPU procedure
* Ovarian stimulation with GnRH antagonist protocol
* Agree to participate in the randomization
Exclusion Criteria:
* Uterine abnormalities such as unicornuate, bicornuate uterus, didelphys and adenomyosis
* Recent history of any current untreated endocrine abnormality
* Gonadotropin resistance syndrome
* Contraindications of gonadotropins
* Absolute asthernozoospermia
* Cryptozoospermia
* Surgical sperm retrieval
* Previous low fertilization (\< 30%)
* Globozoospermia
* Cycles using donor oocytes
* Preimplantation Genetic Testing (PGT) cycles
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.